MedPath

Iberdomide Vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

Phase 3
Recruiting
Conditions
Multiple Myeloma
Interventions
Registration Number
NCT06216158
Lead Sponsor
University of Heidelberg Medical Center
Brief Summary

The goal of this clinical trial is to compare a maintenance therapy consisting of iberdomide and isatuximab with an iberdomide-only regimen. The trial is the subsequent maintenance therapy to GMMG-HD8/DSMM XIX trial for patients with newly-diagnosed multiple myeloma. The main question it aims to answer is:

• Will the addition of isatuximab lead to decreased amounts of measurable myeloma cells in the bone marrow after two years?

Detailed Description

Prospective, multicentre, randomised, parallel group, open, phase III clinical trial for a maintenance therapy, for patients who underwent an induction therapy and autologous stem cell transplantation in the GMMG-HD8/DSMM XIX trial.

Investigational Medicinal Product: Iberdomid (oral), isatuximab (subcutaneous administration via a wearable injector system).

Randomisation will be performed centrally by GMMG/DSMM offices after verification of the eligibility of the patient. At the time of study inclusion, randomization will be performed into arm A (iberdomide) or arm B (iberdomide + isatuximab). Randomization will be stratified by centrally assessed MRD negativity status (yes vs. no vs. unknown); assessed by NGF from BMA; sensitivity of 10\^-5; independent of standard IMWG response) and number of HDM/ASCT (single vs. tandem).

Patients randomized in arm A will receive 39 cycles of the drug iberdomide, a Cereblon E3 Ubiquitin Ligase Modulating Drug (CELMoD®) that shares structural similarities to the immunomodulatory compounds (IMiDs) such as thalidomide and lenalidomide. Each cycle will last for 29 days. Patients in arm B will receive the same the 39 cycles of iberdomide plus monoclonal anti-CD38 antibody isatuximab subcutaneously. In both arms, patients will receive 20 mg dexamethasone in cycle 1, on the same days as the isatuximab administration in Arm B. End of study will be after 36 months of the maintenance therapy.

There is one primary objective:

- Demonstration of superiority of iberdomide plus isatuximab compared to iberdomide with respect to bone marrow minimal residual disease (MRD) negativity rates (sensitivity 2x10\^-6 via next-generation flow cytometry \[NGF\]) after two years of maintenance therapy.

There is one key secondary objective:

- PFS, defined as time from randomization to disease progression or death from any cause, whichever occurs first.

Further secondary objectives are:

* Rates of sustained MRD negativity (at sensitivity levels of 10-5 and 2x10\^-6 via NGF from BMA) after 1, 2 and 3 years of maintenance therapy.

* Conversion from MRD positive to negative (at sensitivity levels of 10\^-5 and 2x10\^-6 via NGF from BMA).

* Rates of best overall response to treatment (BOR).

* Rates of partial response (PR), very good partial response (VGPR), complete response (CR) and stringent complete response (sCR).

* Time-to-next-treatment (TTNT).

* PFS on subsequent line of therapy.

* Overall survival (OS).

* Improvement of IMWG response categories (PR, VGPR, CR, sCR).

* Proportions of patients in both treatment arms maintaining BOR and CR from baseline.

* Assessment of quality-of-life (QoL) via the EORTC-QLQC30, EORTC-QLQMY20, and EQ-5D-5L questionnaires.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
411
Inclusion Criteria
  • Prior inclusion and treatment within the GMMG-HD8 / DSMM XIX trial
  • Received at least one cycle high dose melphalan therapy (HDM) and autologous stem cell transplantation (ASCT)
  • At least Partial Response (PR) according to IMWG criteria at inclusion in the trial
  • Age of at least 18 years at trial inclusion
  • WHO performance status of 0, 1, or 2
  • Negative pregnancy test at inclusion (women of childbearing potential)
  • For all men and women of childbearing potential: patients must be willing and capable to use adequate contraception during the complete therapy
  • Ability of patient to understand character and individual consequences of the clinical trial
  • Written informed consent (must be available before enrolment in the trial)
Exclusion Criteria
  • Subjects with gastrointestinal disease that may significantly alter the absorption of iberdomide
  • Patient has known hypersensitivity (or contraindication) to any of the components of study therapy that are not amenable to premedication with steroids or H1 blockers and that would prohibit further treatment with these agents (e.g. known intolerance or hypersensitivity to infused proteins products, sucrose, histidine, and polysorbate 80 as well as intolerance to arginine and Poloxamer 188)
  • Patients with a history of serious allergic reaction to another immunomodulatory agent (thalidomide, lenalidomide, or pomalidomide)", as angioedema and severe dermatologic reactions, including Grade 4 rash and exfoliative or bullous rash
  • Patients currently being treated with strong inhibitors or inducers of CYP3A4/5
  • Systemic AL amyloidosis (except for localized AL amyloidosis limited to the skin or the bone marrow), plasma cell leukemia or polyneuropathy, organomegaly, endocrinopathy, monoclonal-protein and skin abnormalities or Waldenström macroglobulinemia.
  • Previous systemic anti-myeloma treatment other than administered within the GMMG-HD8 / DSMM XIX trial (including up to two cycles cycle high dose melphalan therapy (HDM) and autologous stem cell transplantation (ASCT). Local, consolidative radiotherapy for myeloma disease is permitted unless performed in case of progressive disease according to IMWG criteria
  • Severe cardiac dysfunction (NYHA classification III-IV)
  • Significant hepatic dysfunction (ASAT and/or ALAT ≥ 3 times normal level and/or serum bilirubin ≥ 1.5 times normal level if not due to hereditary abnormalities as Gilbert's disease), unless related to MM or HDM/ASCT.
  • Patients with active or uncontrolled hepatitis B or C or detectable liver disease due to hepatitis B or C. In case of history of hepatitis B or C, it must be clarified whether it has been overcome and negative circulating HBV-DNA or HCV-RNA must be provided. Positive hepatitis B status may only be acceptable in absence of circulating HBV-DNA or signs of chronic or acute infection and if an adequate prophylaxis is being implemented during the course of the study. Prophylaxis for patients with history of hepatitis B or C should be set on a patient individual basis.
  • HIV positivity
  • Patients with active, uncontrolled infections
  • Patients with severe renal insufficiency (Creatinine Clearance < 30ml/min) or requiring hemodialysis
  • Patients with peripheral neuropathy or neuropathic pain, grade 2 or higher (as defined by the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE, version 5.0)
  • Patients with a history of any active malignancy during the past 5 years with the exception of following malignancies after curative therapy: basal cell carcinoma of the skin, squamous cell skin carcinoma, stage 0 cervical carcinoma or any in situ malignancy. A history of an early stage malignancy during the past 5 years may be acceptable, however, in this case the GMMG study office has to be consulted prior to study inclusion
  • Patients with acute diffuse infiltrative pulmonary and/or pericardial disease
  • Autoimmune haemolytic anaemia with positive indirect Coombs test or immune thrombocytopenia
  • Platelet count < 75 x 109/l
  • Haemoglobin ≤ 8.0 g/dl, unless related to MM
  • Absolute neutrophil count (ANC) < 1.0 x 109/l (the use of colony stimulating factors within 14 days before the test is not allowed)
  • Corrected serum calcium > 14 mg/dl (> 3.5 mmol/l)
  • Unable or unwilling to undergo thromboprophylaxis
  • Pregnancy and lactation
  • Participant has any concurrent severe and/or uncontrolled medical condition or psychiatric disease that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study or that confounds the ability to interpret data from the study
  • Subjects, who are committed to an institution by virtue of an order issued either by the judicial or the administrative authorities
  • Participation in other interventional clinical trials. This does not include long-term follow-up periods without active drug treatment of previous studies during the last 6 months.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm A: IberdomideIberdomide36 months of oral iberdomide administration; In cycle 1, dexamethasone is added as pre-medication
Arm B: Iberdomide plus isatuximabIberdomide36 months of oral iberdomide plus subcutaneous isatuximab administration; In cycle 1, dexamethasone is added as pre-medication
Arm B: Iberdomide plus isatuximabDexamethasone36 months of oral iberdomide plus subcutaneous isatuximab administration; In cycle 1, dexamethasone is added as pre-medication
Arm B: Iberdomide plus isatuximabIsatuximab36 months of oral iberdomide plus subcutaneous isatuximab administration; In cycle 1, dexamethasone is added as pre-medication
Arm A: IberdomideDexamethasone36 months of oral iberdomide administration; In cycle 1, dexamethasone is added as pre-medication
Primary Outcome Measures
NameTimeMethod
Demonstration of superiority of iberdomide plus isatuximab compared to iberdomide with respect to bone marrow minimal residual disease (MRD).24 months after start of maintenance therapy

The primary objective of this trial is to compare the two-year MRD negativity rate (sensitivity 2x10\^-6 via next-generation flow cytometry \[NGF\]; from bone marrow aspirate) when treated with iberdomide plus isatuximab, with the MRD negativity after treatment with iberdomide only.

Secondary Outcome Measures
NameTimeMethod
Progression-free survival (PFS) from date of randomization.From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months

PFS, defined as time from randomization to disease progression or death from any cause, whichever occurs first.

Trial Locations

Locations (53)

Helios Klinikum Bad Saarow

🇩🇪

Bad Saarow, Germany

Vivantes Klinikum Neukölln, Klinik für Hämatologie und Onkologie

🇩🇪

Berlin, Germany

Helios Klinikum Berlin-Buch

🇩🇪

Berlin, Germany

Vivantes Klinikum Spandau

🇩🇪

Berlin, Germany

Evangelisches Klinikum Bethel

🇩🇪

Bielefeld, Germany

Johanniter Krankenhaus

🇩🇪

Bonn, Germany

Universitätsklinikum Bonn

🇩🇪

Bonn, Germany

Klinikum Chemnitz

🇩🇪

Chemnitz, Germany

Carl-Thiem-Klinikum Cottbus gGmbH, 2. Medizinische Klinik

🇩🇪

Cottbus, Germany

Charité, III. Medizinische Abteilung

🇩🇪

Berlin, Germany

Malteser Krankenhaus

🇩🇪

Flensburg, Germany

Onkologische Schwerpunktpraxis

🇩🇪

Heidelberg, Germany

Gemeinschaftsklinikum Mittelrhein Koblenz

🇩🇪

Koblenz, Germany

Rotkreuzklinikum

🇩🇪

München, Germany

Robert-Bosch-Krankenhaus

🇩🇪

Stuttgart, Germany

Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation

🇩🇪

Aachen, Germany

Klinikum Darmstadt GmbH, Medizinische Klinik V

🇩🇪

Darmstadt, Germany

St. Johannes Hospital Dortmund

🇩🇪

Dortmund, Germany

Universitätsklinikum Carl Gustav Carus Dresden

🇩🇪

Dresden, Germany

Universitätsklinikum Düsseldorf

🇩🇪

Düsseldorf, Germany

Marien Hospital Düsseldorf GmbH, Klinik für Onkologie, Hämatalogie und Palliativmedizin

🇩🇪

Düsseldorf, Germany

KEM I Evang. Kliniken Essen-Mitte gGmbH, Evangelisches Krankenhaus Essen-Werden gGmbH, Klinik für Hämatologie, Onkologie und Stammzelltransplantation

🇩🇪

Essen, Germany

Centrum für Hämatologie und Onkologie Bethanien

🇩🇪

Frankfurt am Main, Germany

Universitätsmedizin Greifswald

🇩🇪

Greifswald, Germany

Katholisches Krankenhaus Hagen

🇩🇪

Hagen, Germany

Universitätsmedizin Halle

🇩🇪

Halle, Germany

Universitätsklinikum Hamburg-Eppendorf, Zentrum für Onkologie

🇩🇪

Hamburg, Germany

Onkologische Schwerpunktpraxis Heidelberg

🇩🇪

Heidelberg, Germany

Universitätsklinikum Heidelberg, Medizinische Klinik V

🇩🇪

Heidelberg, Germany

SLK Kliniken Heilbronn, Medizinische Klinik III

🇩🇪

Heilbronn, Germany

Universitätsklinikum des Saarlandes, Klinik für Innere Medizin 1

🇩🇪

Homburg, Germany

Philipps-Universität Marburg Hämatologie/Onkologie

🇩🇪

Marburg, Germany

Klinikum Hochsauerland

🇩🇪

Meschede, Germany

Kliniken Ostalb

🇩🇪

Mutlangen, Germany

Klinikum der Friedrich-Schiller-Universität Jena, Klinik für Innere Medizin II, Abteilung Hämatologie und internistische Onkologie

🇩🇪

Jena, Germany

Westpfalz-Klinikum

🇩🇪

Kaiserslautern, Germany

Klinikverbund Allgäu, Klinikum Kempten, Hämatologie / Onkologie

🇩🇪

Kempten, Germany

Oncocare, Gemeinschaftspraxis für Hämatologie und Onkologie

🇩🇪

Lebach, Germany

Klinikum der Stadt Ludwigshafen

🇩🇪

Ludwigshafen, Germany

Universitätsklinikum Schleswig-Holstein

🇩🇪

Lübeck, Germany

Universitätsklinikum Magdeburg

🇩🇪

Magdeburg, Germany

Universitätsklinikum Mannheim, III. Medizinische Klinik

🇩🇪

Mannheim, Germany

Kliniken Maria Hilf

🇩🇪

Mönchengladbach, Germany

Klinikum rechts der Isar der TU München

🇩🇪

München, Germany

Klinikum Oldenburg

🇩🇪

Oldenburg, Germany

Krankenhaus Barmherzige Brüder Regensburg, Klinik für Onkologie und Hämatologie

🇩🇪

Regensburg, Germany

Universitätsklinikum Regensburg

🇩🇪

Regensburg, Germany

Onkologische Schwerpunktpraxis Speyer

🇩🇪

Speyer, Germany

Klinikum der Landeshauptstadt Stuttgart - Katharinenhospital

🇩🇪

Stuttgart, Germany

Universitätsklinikum Tübingen

🇩🇪

Tübingen, Germany

Schwarzwald Baar Klinikum

🇩🇪

Villingen-Schwenningen, Germany

University of Würzburg, Med. Klinik und Poliklinik II

🇩🇪

Würzburg, Germany

Brüderkrankenhaus St. Josef

🇩🇪

Paderborn, Germany

© Copyright 2025. All Rights Reserved by MedPath